TABLE 3.
Association of TMAO with all‐cause mortality, assessed with Cox proportional hazard ratios in subjects with NAFLD (FLI ≥ 60)
| TMAO per 1 Ln SD increment | T1 | T2 | T3 | ||||
|---|---|---|---|---|---|---|---|
| Participants, n | 1598 | 533 | 532 | 533 | |||
| Events, n | 133 | 25 | 45 | 63 | |||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||
| Crude model | 1.41 (1.18, 1.69) | <.001 | (ref) | 1.80 (1.10, 2.93) | .01 | 2.55 (1.60, 4.05) | <.001 |
| Model 1 | 1.25 (1.04, 1.49) | .01 | (ref) | 1.66 (1.02, 2.70) | .04 | 2.16 (1.36, 3.44) | .01 |
| Model 2 | 1.24 (1.04, 1.48) | .02 | (ref) | 1.66 (1.02, 2.71) | .04 | 2.01 (1.26, 3.21) | .003 |
| Model 3 | 1.23 (1.03, 1.47) | .03 | (ref) | 1.71 (1.04, 2.79) | .03 | 1.96 (1.23, 3.12) | .005 |
| Model 4 | 1.21 (1.01, 1.46) | .04 | (ref) | 1.69 (1.03, 2.77) | .04 | 1.90 (1.18, 3.04) | .008 |
Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs) and P values. Model 1: Model adjusted for age + sex. Model 2: Model 1 + SBP + smoking status + alcohol consumption + cancer history + glucose lowering medication + lipid lowering medication. Model 3: Model 2 + TC + HDL‐C + Glucose. Model 4: Model 3 + albuminuria + reduced eGFR (<90 ml/min/1.73 m2).